|
Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer Clinical research trials and Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer. Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer clinical trial. Participants frequently get the best healthcare available for their Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer  Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer
Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer
For Condition: Lung Cancer,Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: The purpose of this study is to determine whether the investigational drug, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage non-small cell lung cancer
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Disease Characteristics: - Histologically or cytologically confirmed stage IIIB (including those with pleural effusion), IV, or recurrent non-small cell lung cancer (nsclc) - Bidimensionally measurable disease >2cm x 1 cm by conventional CT Scan or >1 cm x 1cm by spiral CT Scan - No tumors in close proximity to major veins or arteries - No sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease - No evidence or history brain metastases Prior/Concurrent Therapy: - Surgery: At least 4 weeks since prior major surgery and recovered - Radiation Therapy: At least 4 weeks since prior radiotherapy and recovered. Prior radiation treatment is permitted providing it is not to the only site of measurable disease or there is documented progression of the previously irradiated site - No prior chemotherapy for NSCLC, investigational agent, or biologic response modifiers - Other: No concurrent chronic steroid therapy or requirement for concomitant anticoagulant therapy except for administration of low dose anticoagulants for maintenance of central venous access Patient Characteristics: - Age at least 26 years. Subjects between 18 years and 26 years will be eligible provided closure of the epiphyses has been demonstrated by an appropriate radiologic scan - Performance Status: ECOG - 0 or 1 - No other cancers (other than NSCLC) diagnosed within the last 3 years except non-melanomatous skin cancer, in situ breast or cervical cancer - Adequate bone marrow, hepatic, and renal function within 14 days prior to enrollment: a) absolute neutrophil count (neutrophils and bands) at least 1.5 x 109 cells/L b) platelets at least 100 x 109 cells/L c) AST and ALT no greater than 5.0 x the upper limit of normal (ULN) d) total bilirubin no greater than 1.5 x the upper limit of normal e) serum creatinine no greater than 1.5 x ULN or calculated creatinine clearance >= 60 ml/min f) serum albumin > 3.2 g/dl - No gastrointestinal abnormalities including such as: a) inability to take oral medication b) requirement for intravenous alimentation c) prior surgical procedures affecting absorption d) Treatment for active peptic ulcer disease in the past 6 months e) active gastrointestinal bleeding, unrelated to cancer, as evidenced by either hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy f) malabsorption syndromes g) prior gastric resection - No serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment - Cardiovascular: No significant active cardiac disease within the previous 6 months or serious cardiac arrhythmias. No history of hemorrhage or thrombotic event (including TIAs) in the past 12 months - No known or suspected hypersensitivity to agents that contain Cremophor® (polyoxyethylated castor oil) in their formulation - No dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the study requirements - No women who are pregnant or breast-feeding. Women of child bearing potential must have a negative pregnancy test within 72 hours of start of study therapy. Fertile males must use adequate method of contraception - Written and voluntary informed consent
Total Enrollment: 87
Location and Contact Information:
Pfizer Investigational Site *Recruiting*
Greenbrae, California, 94904
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Lebanon, Tennessee, 37087
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Nashville, Tennessee, 37205
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Stony Brook, New York, 11794
United States
Recruiting
Pfizer Investigational Site *Recruiting*
San Mateo, California, 94402
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Greenbrae, California, 94904
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Tampa, Florida, 33612
United States
Recruiting
Pfizer Investigational Site *Recruiting*
San Pablo, California, 94806
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Nashville, Tennessee, 37211
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Nashville, Tennessee, 37203
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Hermitage, Tennessee, 37076
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Murfreesboro, Tennessee, 37130
United States
Recruiting
Pfizer Investigational Site *Recruiting*
San Pablo, California, 94806
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Nashville, Tennessee, 37203
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Nashville, Tennessee, 37207
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Gallatin, Tennessee, 37066
United States
Recruiting
Additional Information:
Study ID Numbers: A3521002;
Study Start Date: August 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00074854
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Vaccine Therapy with Tumor Specific Mutated P53 or Ras Peptides Alone or in Combination with Cellular Immunotherapy with Peptide Activated Lymphocytes (PAL Cells) Along with Subcutaneous IL-2
2. A Phase I Study To Test The Safety Of DAVANAT With and Without 5-Fluorouracil In Patients With Solid Tumors
3. ABX-EGF in Combination with Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
4. Depsipeptide to Treat Lung Cancer
5. CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Tennessee Clinical Trials
Other Hermitage Clinical Trials
Study of an oral tyrosine kinase inhibitor of VEGFR-2 for the treatment of advanced stage non-small cell lung cancer
|
|
|
|
|
|
|
|
